Evidence map›Paper›PMID 28875476›Full record

ReviewJournal of nephrology2018

Treatment of primary membranous nephropathy: where are we now?

Andrea Angioi, Nicola Lepori, Ana Coloma López, Sanjeev Sethi, Fernando C Fervenza, Antonello Pani

Abstract readReview
PubMed Publisher
In one paragraph

Review in Journal of nephrology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Andrea AngioiDivision of Nephrology and Dialysis, Azienda Ospedaliera G. Brotzu, Piazzale Ricchi n 1, 09100, Cagliari, Italy.
Nicola LeporiDivision of Nephrology and Dialysis, Azienda Ospedaliera G. Brotzu, Piazzale Ricchi n 1, 09100, Cagliari, Italy.
Ana Coloma LópezDivision of Nephrology and Hypertension, Mayo Clinic, Rochester, USA.
Sanjeev SethiDepartment of Anatomic Pathology, Mayo Clinic, Rochester, MN, USA.
Fernando C FervenzaDivision of Nephrology and Hypertension, Mayo Clinic, Rochester, USA.
Antonello PaniDivision of Nephrology and Dialysis, Azienda Ospedaliera G. Brotzu, Piazzale Ricchi n 1, 09100, Cagliari, Italy. antonellopani@aob.it.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the last 10 years, basic science and clinical research have made important contributions to the understanding and management of primary membranous nephropathy (MN). The identification of antibodies directed against the M-type phospholipase A

Indexed as

Adrenal Cortex HormonesAdrenocorticotropic HormoneAntineoplastic Agents, AlkylatingAntineoplastic Agents, ImmunologicalAutoantibodiesCalcineurin InhibitorsChlorambucilCyclophosphamideGlomerulonephritis, MembranousHumansImmunosuppressive AgentsMycophenolic AcidPrognosisReceptors, Phospholipase A2RituximabAdrenal Cortex HormonesAdrenocorticotropic HormoneAntineoplastic Agents, AlkylatingAntineoplastic Agents, ImmunologicalAutoantibodiesCalcineurin InhibitorsChlorambucilCyclophosphamideImmunosuppressive AgentsMycophenolic AcidPLA2R1 protein, humanReceptors, Phospholipase A2RituximabGlomerulopathiesImmunosuppressionMembranous glomerulonephritisRenal diseases

Identifiers

PMID28875476

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.